Drug Trial Radar · NCT04375813
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Jan 25, 2021
Primary completion
Jan 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Robert SvatekAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without adversely affecting patient-reported outcomes and quality of life.
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
eRapaDrug
0.5mg eRapa (encapsulated rapamycin) oral capsules
PlacebosDrug
placebo capsules visually identical to eRapa oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine 1-year Recurrence Free Survival (RFS) rateTime frame: 1 year
- Change in Urinary Quality of LifeTime frame: Scored at baseline and months 3, 6, 12 and 24. For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
- Change in Cognitive FunctionTime frame: EXIT will be scored at baseline and on months 12 and 24.For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
- Change in Cognitive FunctionTime frame: SLUMS will be scored at baseline and on months 12 and 24.For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
- Change in Cognitive FunctionTime frame: TAPS will be scored at baseline and on months 6, 12, and 24. For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
- Change in cytoscopy consistent with recurrence (time to recurrence)Time frame: Patients will undergo office-based cystoscopy with urine cytology every 3 months for the first 2 years, then every 6 months for 2 years, and at year 5, with biopsies per standard of care if necessary.
- Change in Short Physical Performance BatteryTime frame: SPPB will be scored at baseline and on months 6, 12, and 24. For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
- Change in Handgrip StrengthTime frame: Handgrip Strength will be scored at baseline and on months 6, 12, and 24. For any subject who has a recurrence after enrollment, but prior to completing a full year of dosing at Visit 6, this will also be measured at the End of Treatment visit.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UT Southwestern Medical Center
Dallas, Texas
UT Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.